Mr. Roderick Matheson reports

MARVEL BIOSCIENCES RECEIVES NOTICE OF ALLOWANCE FOR US PATENT APPLICATION COVERING COMPOSITION OF MATTER FOR ITS LEAD THERAPEUTIC CANDIDATE MB-204

Marvel Biosciences Corp. and its wholly owned subsidiary, Marvel Biotechnology Inc., has received an issuance from the U.S. Patent Office of patent No. 12,570,656 B2 for MB-204 granting broad composition of matter and methods of use claims titled "Purine Compounds for Treating Disorders."

"This is the third major jurisdiction that has granted us a composition of matter patent for our lead molecule MB-204," commented Marvel's chief executive officer, Rod Matheson. "We are very pleased to be granted this patent in the U.S., which is critical to executing our business development goals. Strong intellectual property is one of those key components pharmaceutical partners want to see when looking to consecrate a deal with a company such as Marvel."

The issuance of a United States composition of matter patent represents a critical milestone for Marvel, marking the third patent issuance following Japan and China jurisdictions (refer to the company's press releases dated Feb. 3, 2026, and Aug. 18, 2025), as it significantly strengthens the IP protection surrounding MB-204. composition of matter claims are widely regarded as the strongest form of pharmaceutical patent protection, providing the potential for long-term market exclusivity once the compound reaches commercialization. This third patent issuance meaningfully enhances the strategic and economic value of the company's lead asset and supports Marvel's broader strategy of advancing differentiated therapeutics with foundational intellectual property positions, creating a defensible platform asset that could underpin future clinical development, partnerships, licensing and long-term shareholder value creation.

MB-204 is a novel fluorinated analogue of the approved adenosine A2A receptor antagonist Istradefylline which is used for the treatment of Parkinson's Disease. MB-204 has demonstrated superior pharmacokinetics and completed preclinical toxicology testing and has shown excellent preclinical efficacy studies in depression and multiple models of autism including Rett Syndrome. The compound is currently being tested in Fragile X models. Currently, around one in 36 children at age eight have been diagnosed with autism spectrum disorder which underscores the urgency for new agents. Combined with encouraging preclinical data, the growing patent estate around MB-204 further supports Marvel's strategy of developing novel therapeutics for neurological and neurodevelopmental disorders with significant unmet medical need.

About Marvel Biosciences Corp.

Marvel Biosciences, through its wholly owned subsidiary Marvel Biotechnology, is a Calgary-based biotechnology company developing new treatments for neurological diseases and neurodevelopmental disorders. The company's lead drug candidate, MB-204, is a novel fluorinated derivative version of Istradefylline, an approved Parkinson's drug and the only adenosine A2A receptor blocker currently on the market.

Research shows that blocking the A2A receptor may help treat conditions such as autism, depression and Alzheimer's disease. Marvel is also exploring MB-204's potential in rare disorders like Rett syndrome and Fragile X syndrome, aiming to bring new options to patients with few effective treatments.

We seek Safe Harbor.